APNHY
Price
$6.37
Change
+$0.16 (+2.58%)
Updated
Aug 12 closing price
Capitalization
2.84B
YCBD
Price
$0.76
Change
-$0.09 (-10.59%)
Updated
Aug 15 closing price
Capitalization
6.74M
Interact to see
Advertisement

APNHY vs YCBD

Header iconAPNHY vs YCBD Comparison
Open Charts APNHY vs YCBDBanner chart's image
Aspen Pharmacare Holdings
Price$6.37
Change+$0.16 (+2.58%)
Volume$190
Capitalization2.84B
CBDMD
Price$0.76
Change-$0.09 (-10.59%)
Volume$219.62K
Capitalization6.74M
APNHY vs YCBD Comparison Chart in %
Loading...
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APNHY vs. YCBD commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and YCBD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (APNHY: $6.36 vs. YCBD: $0.76)
Brand notoriety: APNHY and YCBD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: APNHY: 5% vs. YCBD: 256%
Market capitalization -- APNHY: $2.84B vs. YCBD: $6.74M
APNHY [@Pharmaceuticals: Generic] is valued at $2.84B. YCBD’s [@Pharmaceuticals: Generic] market capitalization is $6.74M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APNHY’s FA Score shows that 1 FA rating(s) are green whileYCBD’s FA Score has 1 green FA rating(s).

  • APNHY’s FA Score: 1 green, 4 red.
  • YCBD’s FA Score: 1 green, 4 red.
According to our system of comparison, YCBD is a better buy in the long-term than APNHY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APNHY’s TA Score shows that 2 TA indicator(s) are bullish while YCBD’s TA Score has 3 bullish TA indicator(s).

  • APNHY’s TA Score: 2 bullish, 6 bearish.
  • YCBD’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, YCBD is a better buy in the short-term than APNHY.

Price Growth

APNHY (@Pharmaceuticals: Generic) experienced а +2.84% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -14.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APNHY($2.84B) has a higher market cap than YCBD($6.74M). APNHY has higher P/E ratio than YCBD: APNHY (11.05) vs YCBD (1.48). APNHY YTD gains are higher at: -22.942 vs. YCBD (-74.793). APNHY has higher annual earnings (EBITDA): 8.02B vs. YCBD (1.68M). APNHY has more cash in the bank: 6.8B vs. YCBD (1.77M). YCBD has less debt than APNHY: YCBD (1.15M) vs APNHY (35.5B). APNHY has higher revenues than YCBD: APNHY (45.5B) vs YCBD (19.6M).
APNHYYCBDAPNHY / YCBD
Capitalization2.84B6.74M42,185%
EBITDA8.02B1.68M478,354%
Gain YTD-22.942-74.79331%
P/E Ratio11.051.48745%
Revenue45.5B19.6M232,143%
Total Cash6.8B1.77M385,496%
Total Debt35.5B1.15M3,100,437%
FUNDAMENTALS RATINGS
APNHY vs YCBD: Fundamental Ratings
APNHY
YCBD
OUTLOOK RATING
1..100
3056
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6493
P/E GROWTH RATING
1..100
931
SEASONALITY SCORE
1..100
7575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APNHY's Valuation (10) in the null industry is somewhat better than the same rating for YCBD (49) in the Other Consumer Services industry. This means that APNHY’s stock grew somewhat faster than YCBD’s over the last 12 months.

APNHY's Profit vs Risk Rating (100) in the null industry is in the same range as YCBD (100) in the Other Consumer Services industry. This means that APNHY’s stock grew similarly to YCBD’s over the last 12 months.

APNHY's SMR Rating (99) in the null industry is in the same range as YCBD (100) in the Other Consumer Services industry. This means that APNHY’s stock grew similarly to YCBD’s over the last 12 months.

APNHY's Price Growth Rating (64) in the null industry is in the same range as YCBD (93) in the Other Consumer Services industry. This means that APNHY’s stock grew similarly to YCBD’s over the last 12 months.

YCBD's P/E Growth Rating (1) in the Other Consumer Services industry is significantly better than the same rating for APNHY (93) in the null industry. This means that YCBD’s stock grew significantly faster than APNHY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APNHYYCBD
RSI
ODDS (%)
Bullish Trend 3 days ago
58%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
60%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
58%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FINV9.330.51
+5.78%
FinVolution Group
GSIT3.190.05
+1.59%
GSI Technology
RIVN12.240.18
+1.49%
Rivian Automotive
KRT25.35-0.09
-0.35%
Karat Packaging
NAAS2.75-0.05
-1.79%
NaaS Technology Inc

APNHY and

Correlation & Price change

A.I.dvisor tells us that APNHY and TEVA have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TEVA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APNHY
1D Price
Change %
APNHY100%
N/A
TEVA - APNHY
23%
Poorly correlated
+1.82%
PRFX - APNHY
18%
Poorly correlated
-4.93%
QNTM - APNHY
17%
Poorly correlated
+0.45%
ALID - APNHY
7%
Poorly correlated
N/A
YCBD - APNHY
0%
Poorly correlated
-10.98%
More

YCBD and

Correlation & Price change

A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with AGYTF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then AGYTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YCBD
1D Price
Change %
YCBD100%
-10.98%
AGYTF - YCBD
39%
Loosely correlated
N/A
TLRY - YCBD
25%
Poorly correlated
-12.71%
DERM - YCBD
23%
Poorly correlated
-4.27%
CRON - YCBD
23%
Poorly correlated
-5.95%
SXTC - YCBD
21%
Poorly correlated
+1.27%
More